Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act (Wertpapierhandelsgesetz)
12/16/2009
Ad-hoc: Biofrontera AG closes placement of capital increase
12/2/2009
Ad-hoc: Phase III data of BF-200 ALA demonstrate superiority against Metvix
11/20/2009
Ad-hoc: Biofrontera AG determines conditions of the capital increase
9/25/2009
Ad-hoc: Biofrontera AG successfully completes capital increase
9/9/2009
Ad-hoc: Biofrontera AG successfully places capital increase
8/14/2009
Ad-hoc: Result of the optional offer to exchange the 8%-convertible bond 2005/2010
7/29/2009
Ad-hoc: Extension of the optional offer for the replacement of Biofrontera’s 8% convertible bond 2005/2010
7/27/2009
Ad-hoc: Clinical study with BF-derm1 shows efficacy in severe chronic urticaria
7/24/2009
Ad-hoc: Biofrontera AG decides to increase its base capital
7/23/2009
Ad-hoc: Holders of the 8% convertible bond 2005/2010 of Biofrontera agree with modifications of the bond conditions
7/2/2009
Ad-hoc: Decisions of the bond holder meeting of Biofrontera’s 8% convertible bond 2005/2010
6/29/2009
Ad-hoc: Biofrontera AG offers optional replacement and restructuring of the 8% convertible bond 2005/2010
6/9/2009
Ad-hoc: Biofrontera creates option bond / planned restructuring of the 8% convertible bond 2005/2010
5/7/2009
Ad-hoc: Biofrontera AG places capital increase
2/24/2009
Ad-hoc: Conversion of Biofrontera bonds
1/14/2009
Ad-hoc: Placement of a capital increase from authorized capital
